KHRISTOPHER FUSELIER: Open Payments
NPI 1326637737 · CROWLEY, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,166 in 62 payments from 10 companies in 2025. Trend: 2023 $259 · 2024 $169 · 2025 $1,166
Food & beverage: $1,154Education: $12
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 20 | $456 |
| ABBVIE INC. | 17 | $196 |
| Alkermes, Inc. | 13 | $161 |
| Otsuka America Pharmaceutical, Inc. | 2 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $74 |
| Janssen Pharmaceuticals, Inc | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Gilead Sciences, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
Products named: FANAPT, VRAYLAR, ARISTADA, REXULTI, CAPLYTA, SPRAVATO, HETLIOZ, Auvelity.
Industry payments across LA — which companies pay providers there.
